Soligenix, Inc. (SNGX)
$
1.27
Key metrics
Financial statements
Free cash flow per share
-2.7556
Market cap
4.1 Million
Price to sales ratio
1.8 Thousand
Debt to equity
0.0219
Current ratio
11.2560
Income quality
1.0166
Average inventory
0
ROE
-1.4830
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases in the United States. The company reported a net loss of -$8,676,000.00 indicating challenges in its operations. In terms of core operations, the gross profit stands at -$125,000.00 which highlights the company's profitability from its main activities. The cost of revenue for the company is $119,371.00 showcasing its production and operational expenses associated with the development and commercialization of its products. Furthermore, the net income ratio is -72.68 reflecting the company's profitability margin and operational efficiency. Additionally, the net total of other income and expenses is $763,807.00 which provides insight into the organization’s non-core financial activities. Soligenix operates within two segments, Specialized BioTherapeutics and Public Health Solutions, developing innovative therapies such as SGX301 (HyBryte) for cutaneous T-cell lymphoma and SGX942 for inflammatory diseases, among others. Soligenix's stock is affordable at $1.27 making it an attractive option for budget-conscious investors. However, it has a low average trading volume of 959,024.00 indicating lower market activity, which could affect liquidity for potential investors. With a market capitalization of $4,145,725.00 the company is classified as a small-cap player, which often entails a different risk and growth profile compared to larger corporations. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its innovative therapies and public health solutions. Additionally, it belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical space, which plays a vital role in addressing unmet medical needs and advancing healthcare solutions.
Is Soligenix, Inc. (SNGX) a good investment?
Investing in Soligenix, Inc. (SNGX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Soligenix, Inc. (SNGX)'s stock forecast?
Analysts predict Soligenix, Inc. stock to fluctuate between $1.09 (low) and $7.61 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Soligenix, Inc.'s market capitalization?
As of 2025-07-11, Soligenix, Inc.'s market cap is $4,145,725, based on 3,264,350 outstanding shares.
How does Soligenix, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Soligenix, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Soligenix, Inc. (SNGX) stock?
To buy Soligenix, Inc. (SNGX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SNGX. Place an order (Market, Limit, etc.).
What is the best time to invest in Soligenix, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Soligenix, Inc. stock ever split?
Soligenix, Inc.'s last stock split was 1:16 on 2024-06-06.
How did Soligenix, Inc. perform in the last earnings report?
Revenue: $119,371 | EPS: -$5.23 | Growth: -58.69%.
Where can I find Soligenix, Inc.'s investor relations reports?
Visit https://www.soligenix.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Soligenix, Inc.?
You can explore historical data from here
What is the all-time high and low for Soligenix, Inc. stock?
All-time high: $594.61 (2021-02-16) | All-time low: $1.09 (2025-07-08).
What are the key trends affecting Soligenix, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
PRINCETON, N.J. , July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J.
prnewswire.com
Active Ingredient Manufacturing Transfer to the U.S. Complete PRINCETON, N.J. , July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling).
globenewswire.com
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today spotlights the efforts of Ellen Kim, M.D., Lead Principal Investigator for the Company's Phase 3 FLASH (1 and 2) studies in early stage cutaneous T-cell lymphoma (CTCL), in advancing HyBryte™ (synthetic hypericin) as a potential new therapy for patients living with mycosis fungoides (MF), the most common form of CTCL.
prnewswire.com
PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025.
prnewswire.com
Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL).
prnewswire.com
Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today a publication describing the preclinical efficacy of CiVax™, a thermostabilized subunit vaccine against SARS-CoV-2.
prnewswire.com
PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2024.
prnewswire.com
Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J. , March 6, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its lead investigators for the cutaneous T-cell lymphoma (CTCL) and psoriasis programs are presenting findings from recent supportive trials with HyBryte™ (synthetic hypericin) in the treatment of CTCL and SGX302 (synthetic hypericin) in the treatment of mild-to-moderate psoriasis.
See all news
